Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
{{output}}
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic thera... ...
